Objective

To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.

Methods

A systematic comprehensive search was performed without language limitation up to 14 December 2020. We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults. Meta-analysis was performed using the Stata software (Stata Corp. College Station, Texas, USA).

Results

Seven arms were included, encompassing postmenopausal women with type 2 diabetes mellitus, postmenopausal women with breast cancer, healthy postmenopausal women, and healthy elderly men. Raloxifene therapy significantly reduced IGF-1 levels (WMD: −2.92 nmol/L, 95% CI: −3.49, −2.35, p < 0.001) compared to placebo. Raloxifene dosage ˃60 mg/day (WMD: −3.29 ng/mL, 95% CI: −3.50 to −3.08, I² = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: −2.29 ng/mL, 95% CI: −2.90 to −1.69, I² = 16%). Moreover, intervention duration ˃26 weeks (WMD: −3.48 ng/mL, 95% CI: −5.26 to −1.69, I² = 0.0%) reduced IGF-1 levels more than ˂26 weeks (WMD: −2.55 ng/mL, 95% CI: −3.31 to −1.79, I² = 92%). In contrast, overall results from the random-effects model did not suggest a significant change in IGFBP-3 levels upon raloxifene therapy.

Conclusion

Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels.

中文翻译：

---

雷洛昔芬给药对血清胰岛素样生长因子-1和胰岛素样生长因子结合蛋白3水平的影响：随机对照试验的系统评价和荟萃分析

客观的

确定雷洛昔芬给药对胰岛素样生长因子-1 (IGF-1) 和胰岛素样生长因子结合蛋白3 (IGFBP-3) 水平的影响。

方法

截至 2020 年 12 月 14 日，我们在没有语言限制的情况下进行了系统的全面搜索。我们仅纳入了评估雷洛昔芬对成人 IGF-1 和 IGFBP-3 影响的试验。使用 Stata 软件 (Stata Corp. College Station, Texas, USA) 进行 Meta 分析。

结果

包括七组，包括患有 2 型糖尿病的绝经后妇女、患有乳腺癌的绝经后妇女、健康的绝经后妇女和健康的老年男性。与安慰剂相比，雷洛昔芬治疗显着降低了 IGF-1 水平（WMD：-2.92 nmol/L，95% CI：-3.49，-2.35，p  < 0.001）。雷洛昔芬剂量 ˃60 mg/天（WMD：-3.29 ng/mL，95% CI：-3.50 至 -3.08，I ²  = 0.0%）将 IGF-1 水平降低超过 60 mg/天（WMD：-2.29 ng/ mL，95% CI：-2.90 至 -1.69，I ²  = 16%)。此外，干预持续 ˃26 周（WMD：-3.48 ng/mL，95% CI：-5.26 至 -1.69，I ²  = 0.0%）降低 IGF-1 水平超过 ˂26 周（WMD：-2.55 ng/mL , 95% CI: -3.31 至 -1.79, I ² = 92%）。相比之下，随机效应模型的总体结果并未表明雷洛昔芬治疗后 IGFBP-3 水平的显着变化。

结论

雷洛昔芬治疗显着降低了血清 IGF-1 水平，但 IGFPB-3 水平没有变化。